Ethambutol toxicity exacerbating the phenotype of CMT2A2
Authors:
- Elaine M. BinkleyEBElaine M. Binkley
- Avrom EpsteinAEAvrom Epstein
- W. David ArnoldWAW. David Arnold
- Victoria H. LawsonVLVictoria H. Lawson
- 4 June 2013
- journal article
- case report
- Published by Wiley in Muscle & Nerve
- Vol. 48 (1) , 140-144
Abstract
Introduction: CMT2A2 is associated with mutations in the mitofusin 2 gene, which encodes a protein involved in mitochondrial fusion. Ethambutol is an antimycobacterial agent associated with toxic optic neuropathies. Ethambutol‐induced optic neuropathy occurs in patients with mutations in a related fusion gene, OPA1, which is responsible for autosomal dominant optic atrophy. Methods: We describe a patient with CMT2A2 (MFN2 mutation: T669G, F223L) who developed accelerated weakness, vocal cord paralysis, and optic atrophy after receiving ethambutol. Results: Deterioration began within months of initiating ethambutol therapy. After discontinuation of ethambutol, neurologic deterioration stabilized with subsequent improvement in visual fields. Conclusions: CMT2A2 is part of a group of genetic disorders which share an association with the process of mitochondrial fusion. This case shows that patients with CMT2A2, and possibly other mitochondrial fusion defects, may be uniquely susceptible to ethambutol‐induced neurotoxicity. This has implications regarding the underlying pathophysiology of mitochondrial fusion defects. Muscle Nerve, 2013Keywords
This publication has 28 references indexed in Scilit:
- Physiological functions of mitochondrial fusionAnnals of the New York Academy of Sciences, 2010
- Ethambutol-induced optic neuropathy linked to OPA1 mutation and mitochondrial toxicityMitochondrion, 2010
- Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseasesHuman Molecular Genetics, 2009
- Mitochondrial fusion and function in Charcot–Marie–Tooth type 2A patient fibroblasts with mitofusin 2 mutationsExperimental Neurology, 2008
- Medication-induced exacerbation of neuropathy in Charcot Marie Tooth DiseaseJournal of the Neurological Sciences, 2006
- Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2Annals of Neurology, 2006
- Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 geneNeurology, 2005
- Mitochondrial GTPase mitofusin 2 mutation in Charcot?Marie?Tooth neuropathy type 2AHuman Genetics, 2004
- Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2ANature Genetics, 2004
- Vincristine NeurotoxicityNew England Journal of Medicine, 1972